Insulin Detemir Action in Cerebro

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of this study is to test the hypothesis that subcutaneous administration of insulin detemir, as compared to insulin NPH, leads to a more pronounced effect on cerebral glucose metabolism and/or cerebral blood flow in brain regions associated with appetite regulation, to account for the reported difference in weight.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: VU University Medical Center
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 1 diabetic patients;

• Diabetes duration =/> 1 year;

• HbA1c ~ 7,5%;

Exclusion Criteria:

• Recent onset of DM;

• BMI < 18 OR > 35 kg/m2;

• T2DM;

• History of major heart/renal disease;

• Severe untreated proliferative retinopathy;

• History of recurrent severe hypoglycaemia;

• (History of) brain disorders;

• Alcohol abuse,(History of) drug abuse, benzodiazepines, selective beta-blockers, oral steroids, oral anticoagulants;

• Current psychiatric disease/treatment;

• (history of) eating disorders;

• History of severe head trauma accompanied by loss of consciousness;

• Any endocrine disease not well controlled for at least 3 months;

• Inability to undergo MRI;

• Visual acuity < 0.3;

• Known or suspected allergy to trial product or related products